Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2917076 | 1.00 | HTT (0.51) | HTTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL10448019 | 0.92 | HTT (0.56) | HTTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL7271033 | 0.89 | KMT2A (0.52) | HTTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL1399018 | 0.88 | HTT (0.50) | HTTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL7286337 | 0.88 | HTT (0.50) | HTTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL1399017 | 0.88 | HTT (0.50) | HTTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL13774925 | 0.88 | KMT2A (0.47) | HTTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL1399012 | 0.87 | HTT (0.49) | HTTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL1399015 | 0.87 | HTT (0.49) | HTTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL8915981 | 0.86 | HTT (0.50) | HTTMEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042286-B1 | GAMMA-GLUTAMYL AND BETA-ASPARTYL CONTAINING IMMUNOMODULATOR COMPOUNDS AND METHODS THEREWITH | CRAGMONT PHARMACEUTICALS LLC (US) | 2010-08-25 | — | — | EP | disclosed |
| US-6569893-B2 | Administering to a patient a triptolide or its derivatives, containing an amino acid or oligopeptide moiety for the treatment of cancer and autoimmune deseases, or inhibition of transplant rejection, graft versus host disease | PHARMAGENESIS, INC. | 2003-05-27 | — | — | US | disclosed |
| US-20020193419-A1 | Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents | PHARMAGENESIS, INC. | 2002-12-19 | — | — | US | disclosed |
| EP-0737197-B1 | AMINO ALKANOIC ESTERS OF RAPAMYCIN | AMERICAN HOME PROD (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1042286-A1 | GAMMA-GLUTAMYL AND BETA-ASPARTYL CONTAINING IMMUNOMODULATOR COMPOUNDS AND METHODS THEREWITH | Wei, Edward T. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033799-A1 | GAMMA-GLUTAMYL AND BETA-ASPARTYL CONTAINING IMMUNOMODULATOR COMPOUNDS AND METHODS THEREWITH | WEI EDWARD T (US) | 1999-07-08 | — | — | WO | disclosed |
| US-5916878-A | DIPEPTIDE OF EITHER GAMMA-GLUTAMYL-L-TRYPTOPHAN OR BETA-ASPARTYL-L-TRYPTOPHAN; ADMINISTERING TO THE PATIENTS TO REDUCE THE RISKS INFECTIONS FROM MICROORGANISM | Wei, Edward T. (US) | 1999-06-29 | — | — | US | disclosed |
| US-5389639-A | Immunosuppressants | AMERICAN HOME PRODUCTS COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
| EP-0244836-B1 | TRIPEPTIDE DERIVATIVES | Dainippon Pharmaceutical Co., Ltd. (JP) | 1993-08-18 | — | — | EP | disclosed |
| US-4826814-A | INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-05-02 | — | — | US | disclosed |
| EP-0244836-A2 | Tripeptide derivatives | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193419-A1 | Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents | CCRL2, CCR1, XPNPEP1 | HTT 2792/4885MEN1 2944/4885KMT2A 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.